Oxidative Medicine and Cellular Longevity / 2016 / Article / Tab 2

Review Article

Chlorinated Phospholipids and Fatty Acids: (Patho)physiological Relevance, Potential Toxicity, and Analysis of Lipid Chlorohydrins

Table 2

Survey of selected diseases where myeloperoxidase (MPO) presumably represents a suitable “biomarker.” The alterations of MPO concentration and/or activity are emphasized.

DiseaseChanges of MPOMatrixMethodRef.


Rheumatoid arthritisIncreased activity/concentrationSFELISA[120]
Increased concentrationSerumELISA[121]
Plasma, SFELISA[122]
Increased activitySFNMR[123]

Juvenile idiopathic arthritisIncreased concentrationSerumSerum[124]


Increased concentrationPlasmaELISA[126]
Mixed with lipoproteinsELISA[127]
APIHC; western blot[128]
HPLC, western blot[129]
Increased release by culprit plaque samplesCPELISA[130]
Increased activityAPSpectrophotometry[131]


Increased levelSerumSpectrophotometry[132]
Increased activity at higher G allele, anti-inflammatory effect of mutant A alleleMPO -463 G/A SNPPCR[133]
Increased concentrationPlasmaELISA[134]
Decreased activityNeutrophilic cell lysateSpectrophotometry[135]

Neurodegenerative  diseases

Alzheimer’s diseaseIncreased concentrationPlasmaELISA[136]
ExpressionAstrocytesConfocal microscopy, IHC[137]
Increased ExpressionBrain tissueImmunoblot, IHC, PCR[138]

Parkinson’s diseaseExpressionBrain tissueIHC[139]

Multiple sclerosisIncreased activity/concentrationCerebral CortexColorimetric analysis[140]

Systemic lupus erythematosus

Increased concentrationSerumELISA[121]

Lung diseases

Acute pulmonary tuberculosisIncreased concentrationSerumEIA[143]

COPDIncreased levelsSputumMeta-analysis[144]
ELISA[145, 146]

Cystic fibrosisIncreased concentrationSputumELISA[147]

SF, synovial fluid; AP, atherosclerotic plaque; COPD, chronic obstructive pulmonary disease; CP, culprit plaque; EIA, Enzyme Immunoassay; ELISA, Enzyme-Linked Immunosorbent Assay; HPLC, High Performance Liquid Chromatography; IHC, immunohistochemistry; NMR, Nuclear Magnetic Resonance; SNP, Single Nucleotide Polymorphism.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.